1. 1288. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). (15th December 2022) Authors: Hsu, Ricky K; Phoenix, John; Sinclair, Gary I; Gupta, Samir K; Puga, Ana; Nguyen, Kaitlin; Schubert, Catherine K; Merrill, Deanna; Richardson, David; Nelson, Kate; Reynolds, Maria; Zografos, Laurie; Jean-Louis, Ashley; Garris, Cindy Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 7 (July 2021) Authors: Ogbuagu, Onyema; Ruane, Peter J; Podzamczer, Daniel; Salazar, Laura C; Henry, Keith; Asmuth, David M; Wohl, David; Gilson, Richard; Shao, Yongwu; Ebrahimi, Ramin; Cox, Stephanie; Kintu, Alexander; Carter, Christoph; Das, Moupali; Baeten, Jared M; Brainard, Diana M; Whitlock, Gary; Brunetta, Jason... Journal: Lancet Issue: Volume 8:Issue 7(2021) Page Start: e397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗